US FDA Issues Warning Letter to Glenmark Pharma’s Monroe Factory

Glenmark Pharma says a warning letter was issued to its Monroe, North Carolina, manufacturing facility following an inspection conducted in April and May of 2022.

• Glenmark says it had done a voluntary recall of all its products from this site in August 2021 and since then no product has been commercialized from this factory
  • The warning letter will have no impact on company’s existing revenues and it continues to cooperate with the US FDA

STOCKS TO WATCH

• Glenmark Pharma
• Glenmark Life, as Glenmark Pharma owns about 83% of the company as of end-March: data compiled by bloomberg

To view the ...